4330 La Jolla Village Drive
About Progenity, Inc.
Progenity is a biotechnology company with a market-leading presence in Women’s Health molecular testing and a pipeline of proprietary tests and therapeutic applications under development. Progenity has a portfolio of innovative technologies and tests for pre-eclampsia, genetic carrier testing, inheritable cancer genetics, liquid biopsy and noninvasive prenatal testing (NIPT), all designed to support clinicians in providing excellent patient care.
10 articles with Progenity, Inc.
Progenity Reaches Resolution with Government Related to Past Business, Promotional, and Billing Practices
Progenity, Inc. announced that it has entered into agreements with the Department of Justice and the Department of Health and Human Services that resolve civil and criminal investigations by such agencies related to certain past business, promotional, and billing practices.
5/29/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
5/1/2020Life sciences and pharma companies strengthen their leadership teams and board with this week's Movers & Shakers.
10/25/2019Pharma and life sciences companies strengthen their executive and leadership teams with this week's appointments.
8/9/2019Biopharma companies strengthen their senior leadership teams and boards of directors.
6/7/2019Pharma and biotech companies strengthen their executive and leadership teams with new appointments.
3/1/2019Pharma and biotech companies make changes to leadership roles, with new hires at Agios, Notable, Rapamycin, Confo, AVEO and more.
Progenity, Inc., a privately held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms, announced that Harry Stylli, Ph.D., CEO, will be participating in several upcoming investor conferences.
Company Focused on Diagnostic and Therapeutic Precision Medicine Solutions in Prenatal and Perinatal Healthcare, Oncology, and Gastroenterology
Progenity snagged $125M in funding that will allow the company to accelerate development of its gastrointestinal platform.